year 14, Issue 4 (July - August 2020)                   Iran J Med Microbiol 2020, 14(4): 342-347 | Back to browse issues page

‎ 10.30699/ijmm.14.4.342

XML Persian Abstract Print

Investigation of Antiviral Drugs with Direct Effect on RNA Polymerases and Simulation of Their Binding to SARS-CoV-2 (COVID-19) RNA-Dependent RNA Polymerase by Molecular Docking Method
Mohammad Hossein Heydargoy
Microbiology Department, Faculty of Basic Sciences, Islamic Azad University, Shahr-e-Qods Branch, Tehran, Iran , heydoc92@gmail.com
Abstract:   (5492 Views)

Background: Following the outbreak of SARS-CoV (Severe Acute Respiratory Syndrome coronavirus) in 2002 and the outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, we are facing the rapid spread of SARS-CoV-2 (COVID-19) in the world in 2019. Several outbreaks of the virus and its widespread prevalence have necessitated the design of drugs and vaccines in the shortest possible time. This is not possible except by using bioinformatics tools. In this study, the binding of drugs affecting RNA Polymerases to SARS-CoV-2 RNA-dependent RNA polymerase structure was simulated by molecular docking method.
Materials & Methods: The structure of drugs used to treat COVID-19 and their similar structures from the drugbank database received. It was then subjected to molecular docking by AutoDock Vina software, and the structure with the most negative affinity was docked to reconsider its connection location. Finally, the amino acids involved in binding were investigated by Discovery Studio software.
Results: In the test with in silico status, the Rifabutin had the best performance for SARS-CoV-2 RNA-dependent RNA polymerase binding, and the binding site identified for this drug was different from the binding site shown in the PDB database.
Conclusion: Further research on the Rifabutin could be the key to discovering new drugs for COVID-19.

Keywords: COVID-19, SARS-CoV-2, Molecular docking, Structural bioinformatics, Rifabutin
Full-Text [PDF 558 kb]   (1773 Downloads) |   |   Full-Text (HTML)  (1423 Views)  
Type of Study: Original Research Article | Subject: Microbial Bioinformatics
Received: 2020/04/10 | Accepted: 2020/07/27 | ePublished: 2020/07/20
References
1. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nature reviews Microbiology. 2019;17(3):181-92. [DOI:10.1038/s41579-018-0118-9] [PMID] [PMCID]
2. Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet. 2003;362(9393):1353-8. [DOI:10.1016/S0140-6736(03)14630-2]
3. York A. Novel coronavirus takes flight from bats? Nature Reviews Microbiology. 2020:1-. [DOI:10.1038/s41579-020-0336-9] [PMID] [PMCID]
4. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine. 2012;367(19):1814-20. [DOI:10.1056/NEJMoa1211721] [PMID]
5. Coronavirus disease (COVID-2019) situation reports [Internet]. World Health Organization. 9 April 2020.
6. Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA drug design & delivery. 2013;1(1):3-7. [DOI:10.13172/2054-4057-1-1-1119]
7. Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current computer-aided drug design. 2011;7(2):146-57. [DOI:10.2174/157340911795677602] [PMID]
8. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;101615. [DOI:10.1016/j.tmaid.2020.101615] [PMID] [PMCID]
9. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. [DOI:10.1016/j.eng.2020.03.007] [PMID] [PMCID]
10. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences. 2020:117592. [DOI:10.1016/j.lfs.2020.117592] [PMID] [PMCID]
11. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life sciences. 2020:117477. [DOI:10.1016/j.lfs.2020.117477] [PMID] [PMCID]
12. Morris GM, Lim-Wilby M. Molecular docking. Molecular modeling of proteins: Springer; 2008. p. 365-82. [DOI:10.1007/978-1-59745-177-2_19] [PMID]
13. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic acids research. 2018;46(D1):D1074-D82. [DOI:10.1093/nar/gkx1037] [PMID] [PMCID]
14. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry. 2010;31(2):455-61. [DOI:10.1002/jcc.21334] [PMID] [PMCID]
15. PDB ID: 102L SARS-CoV-2 RNA-dependent RNA polymerase in complex with cofactors in reduced condition [Internet]. 8 April 2020.
16. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry. 2009;30(16):2785-91. [DOI:10.1002/jcc.21256] [PMID] [PMCID]
17. Dassault Systèmes BIOVIA DS, 2020 Client, San Diego: Dassault Systèmes, 2020.
18. Novikov FN, Chilov GG. Molecular docking: theoretical background, practical applications and perspectives. Mendeleev Communications. 2009;5(19):237-42. [DOI:10.1016/j.mencom.2009.09.001]
19. Chang Y-C, Tung Y-A, Lee K-H, Chen T-F, Hsiao Y-C, Chang H-C, et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. 2020. [DOI:10.20944/preprints202002.0242.v1]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.